These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 38992789)

  • 1. Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B).
    Stemler J; Yeghiazaryan L; Stephan C; Mohn KG; Carcas-Sansuan AJ; Rodriguez ER; Moltó J; Mitxeltorena IV; Welte T; Zablockienė B; Akova M; Bethe U; Heringer S; Salmanton-García J; Jeck J; Tischmann L; Zarrouk M; Cüppers A; Biehl LM; Grothe J; Mellinghoff SC; Nacov JA; Neuhann JM; Sprute R; Frías-Iniesta J; Negi R; Gaillard C; Saini G; León AG; Mallon PWG; Lammens C; Hotterbeekx A; Loens K; Malhotra-Kumar S; Goossens H; Kumar-Singh S; König F; Posch M; Koehler P; Cornely OA;
    Int J Infect Dis; 2024 Sep; 146():107161. PubMed ID: 38992789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: A randomised VACCELERATE trial in adults ≥75 years (EU-COVAT-1).
    Neuhann JM; Stemler J; Carcas AJ; Frías-Iniesta J; Akova M; Bethe U; Heringer S; Salmanton-García J; Tischmann L; Zarrouk M; Cüppers A; Grothe J; Leon AG; Mallon P; Negi R; Gaillard C; Saini G; Lammens C; Hotterbeekx A; Loens K; Malhotra-Kumar S; Goossens H; Kumar-Singh S; König F; Yeghiazaryan L; Posch M; Koehler P; Cornely OA
    Vaccine; 2023 Nov; 41(48):7166-7175. PubMed ID: 37919141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.
    Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK
    Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network.
    Neuhann JM; Stemler J; Carcas A; Frías-Iniesta J; Bethe U; Heringer S; Tischmann L; Zarrouk M; Cüppers A; König F; Posch M; Cornely OA
    Trials; 2022 Oct; 23(1):865. PubMed ID: 36209129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy.
    Sieghart D; Hana CA; Dürrschmid C; Heinz LX; Haslacher H; Zlesak M; Piccini G; Manenti A; Montomoli E; Jorda A; Fedrizzi C; Hasenoehrl T; Zdravkovic A; Anderle K; Wiedermann U; Drapalik S; Steinbrecher H; Bergmann F; Firbas C; Jordakieva G; Wagner B; Leonardi M; Pierleoni G; Ballini M; Benincasa L; Marchi S; Trombetta C; Perkmann T; Crevenna R; Zeitlinger M; Bonelli M; Aletaha D; Radner H
    J Clin Virol; 2024 Aug; 173():105661. PubMed ID: 38503118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Booster vaccination using bivalent DS-5670a/b is safe and immunogenic against SARS-CoV-2 variants in children aged 5-11 years: a phase 2/3, randomized, active-controlled study.
    Suzuki R; Suda M; Ishida K; Furihata K; Ota A; Takahashi K; Sakakibara S; Nakayama T; Takeshita F
    Front Immunol; 2024; 15():1445459. PubMed ID: 39286253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.
    Salehi M; Alavi Darazam I; Nematollahi A; Alimohammadi M; Pouya S; Alimohammadi R; Khajavirad N; Porgoo M; Sedghi M; Mahdi Sepahi M; Azimi M; Hosseini H; Mahmoud Hashemi S; Dehghanizadeh S; Khoddami V
    Int Immunopharmacol; 2024 Jun; 134():112192. PubMed ID: 38761778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
    Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
    Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants following CoronaVac or ChAdOx1 nCoV-19 primary series.
    Angkasekwinai N; Niyomnaitham S; Sewatanon J; Phumiamorn S; Sukapirom K; Senawong S; Toh ZQ; Umrod P; Somporn T; Chumpol S; Ritthitham K; Jantraphakorn Y; Srisutthisamphan K; Chokephaibulkit K
    Asian Pac J Allergy Immunol; 2024 Sep; 42(3):276-289. PubMed ID: 37466962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
    Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Geers D; Schmitz KS; Garcia Garrido HM; Koopmans MPG; Dalm VASH; Kootstra NA; Huckriede ALW; Lafeber M; van Baarle D; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
    N Engl J Med; 2022 Mar; 386(10):951-963. PubMed ID: 35045226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial.
    Poh XY; Lee IR; Tan CW; Chavatte JM; Fong SW; Goh YS; Rouers A; Wong N; Torres-Ruesta A; Mah SYY; Yeoh AYY; Gandhi M; Rahman N; Chin YQ; Lim JJ; Yoong TJK; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Lim DRX; Chia W; Renia L; Ren EC; Lin RTP; Lye DC; Wang LF; Ng LFP; Young BE
    EBioMedicine; 2024 Sep; 107():105275. PubMed ID: 39137572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BNT162b2 versus mRNA-1273 Third Dose COVID-19 Vaccine in Patients with CKD and Maintenance Dialysis Patients.
    Yau K; Tam P; Chan CT; Hu Q; Qi F; Abe KT; Kurtesi A; Jiang Y; Estrada-Codecido J; Brown T; Liu L; Siwakoti A; Leis JA; Levin A; Oliver MJ; Colwill K; Gingras AC; Hladunewich MA
    Clin J Am Soc Nephrol; 2024 Jan; 19(1):85-97. PubMed ID: 37847518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine schedules in healthy adults: The IMCOVAS randomized clinical trial.
    Steenackers K; Hanning N; Bruckers L; Desombere I; Marchant A; Ariën KK; Georges D; Soentjens P; D'Onofrio V; Hites M; Berens-Riha N; De Coster I; Damme PV
    Vaccine; 2024 Nov; 42(25):126117. PubMed ID: 39019657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
    Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
    Dixit A; Bennett R; Ali K; Griffin C; Clifford RA; Turner M; Poston R; Hautzinger K; Yeakey A; Girard B; Zhou W; Deng W; Zhou H; Schnyder Ghamloush S; Kuter BJ; Slobod K; Miller JM; Priddy F; Das R;
    Lancet Infect Dis; 2024 Jul; 24(7):687-697. PubMed ID: 38518789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
    Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homologous and Heterologous Covid-19 Booster Vaccinations.
    Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
    N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interim safety and immunogenicity analysis of the EuCorVac-19 COVID-19 vaccine in a Phase 3 randomized, observer-blind, immunobridging trial in the Philippines.
    Lovell JF; Miura K; Baik YO; Lee C; Choi Y; Her H; Lee JY; Ylade M; Lee-Llacer R; De Asis N; Trinidad-Aseron M; Ranola JM; De Jesus LZ
    J Med Virol; 2024 Sep; 96(9):e29927. PubMed ID: 39318203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.